Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial
Key facts
- Who runs it
- Zhongshan Hospital (Xiamen), Fudan University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 640 people enrolled
- Started
- 10 Jun 2025
- Ended
- 10 Mar 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tegoprazan
- Amoxicillin
- Tetracycline
- Bismuth
- Record updated
- 19 May 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Age from 18 to 70 years
- H. pylori infection diagnosed by ¹³C-urea breath test or rapid urease test during endoscopy
- The patient infected with Helicobacter pylori has never undergone eradication therapy
Who cannot take part
- Those with concomitant severe cardiovascular, pulmonary, hepatic, renal, or other systemic diseases (e.g., New York Heart Association functional class III-IV, chronic kidney disease stage 3 or higher, Child-Pugh class B or higher cirrhosis)
- Those requiring long-term use of systemic corticosteroids, anticoagulants, or antiplatelet agents (excluding aspirin <100 mg daily)
- Those who have participated in other interventional clinical trials within 3 months prior to enrollment
- Those with a history of drug abuse or alcohol dependence within the past 1 year
- Those with a current or prior history of malignancy at any site
- Those with active gastrointestinal bleeding or unexplained iron deficiency anemia
- Those with severe psychiatric disorders that may compromise compliance with the study
- Patients with a definite history of allergy to the study drugs (tegoprazan, amoxicillin, tetracycline, or bismuth potassium citrate)
- Those who have used any proton pump inhibitors, potassium-competitive acid blockers, antibiotics, bismuth agents, or H₂ receptor antagonists within 4 weeks prior to enrollment
- Pregnant or breastfeeding women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Current first-line Helicobacter pylori eradication protocols involve multidrug regimens comprising a proton pump inhibitor (PPI) or bismuth agent combined with dual antibiotics (e.g., clarithromycin, amoxicillin, quinolones, furazolidone, nitroimidazoles, or tetracycline) administered for 7-14 days. In China, the bismuth-containing quadruple therapy (BQT) remains the standard first-line treatment for H. pylori infection. However, BQT implementation is challenged by polypharmacy burdens, substantial adverse events, and suboptimal treatment adherence. Emerging evidence suggests that simplified dual therapies pairing acid suppressants (PPIs or potassium-competitive acid blockers [P-CABs]) with high-dose amoxicillin achieve comparable eradication rates to BQT while demonstrating superior tolerability and adherence profiles. Notably, the comparative efficacy of tetracycline-based versus amoxicillin-based dual regimens remains unexamined in controlled clinical trials. Our preliminary investigations established that optimized PPI-amoxicillin dual therapy achieves >90% eradication rates in treatment-naïve populations. Building on these findings, this prospective randomized controlled trial will comparatively assess the effectiveness of tegoprazan-a novel P-CAB exhibiting potent acid inhibition-when co-administered with either amoxicillin or tetracycline in H. pylori-positive adults. The investigation aims to establish an evidence framework for streamlining eradication protocols through pharmacodynamic optimization while mitigating antimicrobial resistance development.
The 4 groups in the trial
- Tegoprazan-Amoxicillin Dual TherapyTreatment being tested
Tegoprazan 50 mg orally twice daily (BID) before meals; Amoxicillin 750 mg orally four times daily (QID) after meals; Both administered for 14 consecutive days.
Treatment: Tegoprazan and Amoxicillin
- Tegoprazan-Tetracycline Dual TherapyTreatment being tested
Tegoprazan 50 mg orally twice daily (BID) before meals; Tetracycline 500 mg orally four times daily (QID) after meals; Both administered for 14 consecutive days.
Treatment: Tegoprazan and Tetracycline
- Tegoprazan-Amoxicillin-Tetracycline Triple TherapyTreatment being tested
Tegoprazan 50 mg orally twice daily (BID) before meals; Amoxicillin 1000 mg orally twice daily (BID) after meals; Tetracycline 500 mg orally three times daily (TID) after meals; All administered for 14 consecutive days.
Treatment: Tegoprazan, Amoxicillin, and Tetracycline
- Tegoprazan-Amoxicillin-Tetracycline-Bismuth Quadruple TherapyExisting treatment, for comparison
Tegoprazan 50 mg orally twice daily (BID) before meals; Amoxicillin 1000 mg orally twice daily (BID) after meals; Tetracycline 500 mg orally three times daily (TID) after meals; Bismuth Potassium Citrate Capsules 240 mg orally twice daily (BID) after meals; All administered for 14 consecutive days.
Treatment: Tegoprazan, Amoxicillin, Tetracycline, and Bismuth
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies as First-Line Regimens for Helicobacter Pylori Eradication: A Prospective Randomized Controlled Trial
- Publications
- Record updated
- 19 May 2026